Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2Phase 2 2Phase 4 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Lung Cancer Metastatic 1Carcinoma, Renal Cell 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER × evolocumab × Clear all
NCT05144529 2026-05-05

TOP2101

Duke University

Phase 2 Terminated
19 enrolled 16 charts
Thoracic

Lung Cancer Metastatic

NCT06284564 2026-04-21

A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
10 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡